Immunosuppressive Treatment for an anti-U1 Ribonucleoprotein Antibody-positive Patient with Pulmonary Arterial Hypertension
A 34-year-old woman with pulmonary arterial hypertension (PAH) was admitted to the hospital. She had been diagnosed with PAH three years earlier and treated with triple vasodilator therapy. She was positive for anti-U1 ribonucleoprotein antibodies but did not show any other symptoms associated with autoimmune diseases. Corticosteroid and cyclophosphamide therapy was administered, suspecting the involvement of immunological pathophysiology. After 3 weeks, the mean pulmonary artery pressure decreased from 50 to 38 mmHg without any change in the vasodilators. Immunosuppressive therapy was effective in this patient with PAH with an anti-U1 ribonucleoprotein-antibody-positive response and might be an option for patients with these specific features.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 63(2024), 5 vom: 01. März, Seite 671-676 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matsumoto, Kazuya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.1407-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359687040 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359687040 | ||
| 003 | DE-627 | ||
| 005 | 20240402235720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.1407-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM359687040 | ||
| 035 | |a (NLM)37468249 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matsumoto, Kazuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunosuppressive Treatment for an anti-U1 Ribonucleoprotein Antibody-positive Patient with Pulmonary Arterial Hypertension |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A 34-year-old woman with pulmonary arterial hypertension (PAH) was admitted to the hospital. She had been diagnosed with PAH three years earlier and treated with triple vasodilator therapy. She was positive for anti-U1 ribonucleoprotein antibodies but did not show any other symptoms associated with autoimmune diseases. Corticosteroid and cyclophosphamide therapy was administered, suspecting the involvement of immunological pathophysiology. After 3 weeks, the mean pulmonary artery pressure decreased from 50 to 38 mmHg without any change in the vasodilators. Immunosuppressive therapy was effective in this patient with PAH with an anti-U1 ribonucleoprotein-antibody-positive response and might be an option for patients with these specific features | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-U1 RNP antibody | |
| 650 | 4 | |a corticosteroid | |
| 650 | 4 | |a cyclophosphamide | |
| 650 | 4 | |a pulmonary arterial hypertension | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Antinuclear |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Ribonucleoproteins |2 NLM | |
| 700 | 1 | |a Miyawaki, Yoshia |e verfasserin |4 aut | |
| 700 | 1 | |a Katsuyama, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakadoi, Takato |e verfasserin |4 aut | |
| 700 | 1 | |a Shidahara, Kenta |e verfasserin |4 aut | |
| 700 | 1 | |a Hirose, Kei |e verfasserin |4 aut | |
| 700 | 1 | |a Nawachi, Shoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Asano, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Katsuyama, Eri |e verfasserin |4 aut | |
| 700 | 1 | |a Takano-Narazaki, Mariko |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Akagi, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sada, Ken-Ei |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 63(2024), 5 vom: 01. März, Seite 671-676 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:5 |g day:01 |g month:03 |g pages:671-676 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.1407-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e 5 |b 01 |c 03 |h 671-676 | ||